Hope Rugo, Professor of Medicine and Director of the Breast Oncology Clinical Trials Program at the University of California at San Francisco, shared a post on X:
“On MBCC26 Dennis Slamon keynote speaker discusses the remarkable impact of HER2 targeted RX and CDK4/6i in BC. Even more the impact of pushing barriers and a brilliant mind.
Slamon not only brought us the HER2 target and first/cornerstone effective Rx, but also the incredibly effective CDK4/6i – curing more women with breast cancer worldwide.”
Other articles featuring Hope Rugo on OncoDaily.
